ARA-290: adverse events and evidence limits
The four-week intravenous ARA-290 pilot in sarcoidosis with small-fiber neuropathy symptoms reported no observed adverse events. [1]
This small trial cannot establish rare-event frequencies or long-term risks. [1]
What the studies reported
| Effect | Model or participants | How often or as described | Source |
|---|---|---|---|
| Adverse events overall | Patients with sarcoidosis and small-fiber neuropathy symptoms, intravenous, four-week pilot trial | No observed adverse events were reported; the small trial cannot establish rare-event frequencies or long-term risks | [1] |
References
- Lara Heij et al. (2012). Safety and Efficacy of ARA 290 in Sarcoidosis Patients with Symptoms of Small Fiber Neuropathy: A Randomized, Double-Blind Pilot Study. 10.2119/molmed.2012.00332.